Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Average: 2011-2021

Historic Equity Average for Neurocrine Biosciences (NBIX) over the last 10 years, with Sep 2021 value amounting to $1.3 billion.

  • Neurocrine Biosciences' Equity Average rose 60.51% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 60.51%. This contributed to the annual value of $881.5 million for FY2020, which is 57.75% up from last year.
  • Neurocrine Biosciences' Equity Average amounted to $1.3 billion in Q3 2021, which was up 5.65% from $1.2 billion recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Equity Average ranged from a high of $1.3 billion in Q3 2021 and a low of $281.0 million during Q1 2017.
  • Its 3-year average for Equity Average is $815.0 million, with a median of $765.8 million in 2020.
  • In the last 5 years, Neurocrine Biosciences' Equity Average tumbled by 32.89% in 2017 and then soared by 74.38% in 2021.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Equity Average stood at $359.8 million in 2017, then climbed by 28.99% to $464.1 million in 2018, then spiked by 30.50% to $605.7 million in 2019, then soared by 59.36% to $965.2 million in 2020, then skyrocketed by 60.51% to $1.3 billion in 2021.
  • Its Equity Average was $1.3 billion in Q3 2021, compared to $1.2 billion in Q2 2021 and $1.2 billion in Q1 2021.